SNYSanofiFinished
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Non-relapsing Secondary Progressive Multiple Sclerosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,131 (final count)
- Started
- Sep 24, 2020
- Main results expected
- Aug 29, 2024
- Fully finished
- Aug 29, 2024
- Results posted
- Jun 18, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS)
Measured over: Baseline (Day 1) up to approximately 47 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04411641 · record last updated 2025-07-02 · checked 2026-11-09 15:47 UTC